首頁 > 市場調查報告書 > 製藥

麻醉

市場調查報告書

商品編碼

1622414

全身麻醉劑市場規模、佔有率、成長分析，按藥物類型、給藥途徑、最終用途和地區分類 - 產業預測，2025-2032 年

General Anesthesia Drugs Market Size, Share, Growth Analysis, By Drug Type (Propofol, Sevoflurane), By Route of Administration (Intravenous, Inhaled), By End-Use, By Application, By Region - Industry Forecast 2025-2032

出版日期: 2024年12月22日 | 出版商:

SkyQuest | 英文 260 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023年全身麻醉劑市場規模為55.9億美元，從2024年的57.9億美元成長到2032年的79.7億美元，預計複合年成長率為3.5%。

全身麻醉市場正在經歷顯著成長，這主要是由於手術數量的增加和新麻醉劑的引入。全球每年進行 3.1 億例大型手術，美容和重組手術顯著增加，心血管疾病和慢性腎臟病者對靜脈 (IV)麻醉劑的需求尤其強勁。 PainPass 的 CBD/Lidocaine係列和 Hikma Pharmaceuticals 的Bupivacaine注射液等創新局部麻醉劑進一步促進了市場擴張。此外，PAION AG 的 Byfavo 等程序性鎮靜劑的監管環境也在不斷變化。這些趨勢顯示全身麻醉市場強勁，手術量和產品創新不斷增加。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東/非洲
- 海灣合作理事會國家
- 南非
- 其他中東/非洲

競爭資訊

前5名企業對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司簡介
- 產品系列分析
- 按細分市場分類的佔有率分析
- 收益與前一年同期比較（2022-2024）

主要企業簡介

AstraZeneca（UK）
Baxter International Inc.（USA）
Fresenius SE & Co. KGaA（Germany）
AbbVie Inc.（USA）
B. Braun Melsungen AG（Germany）
Hikma Pharmaceuticals PLC（UK）
Teva Pharmaceutical Industries Ltd.（Israel）
Pfizer Inc.（USA）
Novartis AG（Switzerland）
Mylan NV（USA）
Piramal Enterprises Limited（India）
Eisai Co., Ltd.（Japan）
F. Hoffmann-La Roche Ltd.（Switzerland）
GlaxoSmithKline plc（UK）
Johnson & Johnson（USA）
Merck & Co., Inc.（USA）
Sanofi SA（France）
Sun Pharmaceutical Industries Ltd.（India）
Takeda Pharmaceutical Company Limited（Japan）
Abbott Laboratories（USA）

結論和建議

簡介目錄

Product Code: SQSG30B2035

General Anesthesia Drugs Market size was valued at USD 5.59 Billion in 2023 and is poised to grow from USD 5.79 Billion in 2024 to USD 7.97 Billion by 2032, growing at a CAGR of 3.5% during the forecast period (2025-2032).

The general anaesthesia market is witnessing significant growth, primarily driven by the rising number of surgical procedures and the introduction of new anaesthetic medications. With 310 million major surgeries conducted globally each year and a notable increase in cosmetic and reconstructive procedures, the demand for intravenous (IV) anaesthetics is escalating, particularly for patients with cardiovascular and chronic renal diseases. Innovative local anaesthetic products, such as PainPass's CBD/lidocaine line and Hikma Pharmaceuticals' Bupivacaine HCl Injection, further contribute to market expansion. Additionally, regulatory approvals like PAION AG's Byfavo for procedural sedation demonstrate an evolving landscape. These trends indicate a robust market trajectory for general anaesthesia as both surgical volumes and product innovations continue to rise.

Top-down and bottom-up approaches were used to estimate and validate the size of the General Anesthesia Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

General Anesthesia Drugs Market Segmental Analysis

Global General Anesthesia Drugs Market is segmented by drug type, Route of Administration, end-use, application and region. Based on drug type, the market is segmented into propofol, sevoflurane, desflurane, ketamine, thiopental, etomidate and others. Based on route of administration, the market is segmented into intravenous and inhaled. Based on end-use, the market is segmented into hospitals, ambulatory surgical centers, clinics and others. Based on application, the market is segmented into cardiovascular surgery, orthopedic surgery, neurosurgery, general surgery, cosmetic surgery and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the General Anesthesia Drugs Market

The growth of the general anesthesia drugs market is significantly driven by the rising incidence of cancer in the United States. Recent estimates from the National Cancer Institute indicate that there are currently around 16.9 million cancer survivors, with projections suggesting this figure could reach 22.2 million by 2030. The prevalence of various cancers, including lung, breast, and prostate cancer, is increasing, which leads to a greater need for surgical interventions. As surgeries, particularly for malignant tumors, present the most effective treatment option when cancer is localized, the demand for general anesthesia is expected to rise correspondingly, propelling the market forward.

Restraints in the General Anesthesia Drugs Market

The General Anesthesia Drugs market faces significant restraint due to the associated risks in pediatric patients and pregnant women. Caution is paramount when administering general anesthetics to infants and young children, as their physiological responses differ from adults, influenced by aspects like body composition and the maturation of organ functions. Research has highlighted potential dangers, such as extensive nerve cell death in young animals following prolonged exposure to these drugs, leading to increased scrutiny within human studies. The FDA has further issued warnings about the risks of prolonged or repeated use in children under three and pregnant women, leading healthcare providers to reconsider the adoption of these anesthetic treatments, which may hinder market growth.

Market Trends of the General Anesthesia Drugs Market

The General Anesthesia Drugs market is witnessing significant growth, driven by intensive research and development efforts aimed at enhancing clinical outcomes and patient recovery. Notable studies, such as those from the University of Michigan and Washington University School of Medicine, are assessing the efficacy of existing anesthetics, including inhaled agents and intravenous propofol, to refine usage protocols. This focus on evidence-based practice is poised to improve patient care, making anesthetics safer and more effective. As a result, the market is likely to expand, fueled by innovations that meet the increasing demands of surgical procedures and patient safety standards throughout the forecast period.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Patent Analysis

Global General Anesthesia Drugs Market Size by Drug Type & CAGR (2025-2032)

Market Overview
Propofol
Sevoflurane
Desflurane
Ketamine
Thiopental
Etomidate
Others

Global General Anesthesia Drugs Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Intravenous
- Bolus Injection
- Continuous Infusion
Inhaled
- Volatile Liquids
- Gases

Global General Anesthesia Drugs Market Size by End-Use & CAGR (2025-2032)

Market Overview
Hospitals
Ambulatory Surgical Centers
Clinics
Others

Global General Anesthesia Drugs Market Size by Application & CAGR (2025-2032)

Market Overview
Cardiovascular Surgery
Orthopedic Surgery
Neurosurgery
General Surgery
Cosmetic Surgery
Others

Global General Anesthesia Drugs Market Size & CAGR (2025-2032)

North America (Drug Type, Route of Administration, End-Use, Application)
- US
- Canada
Europe (Drug Type, Route of Administration, End-Use, Application)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Type, Route of Administration, End-Use, Application)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Type, Route of Administration, End-Use, Application)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Type, Route of Administration, End-Use, Application)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius SE & Co. KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
B. Braun Melsungen AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Piramal Enterprises Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments